Investment analysts at StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH – Get Free Report) in a research note issued to investors on Friday. The firm set a “hold” rating on the stock.
Aspira Women’s Health Stock Performance
Shares of AWH stock opened at $0.75 on Friday. The firm has a market cap of $12.50 million, a price-to-earnings ratio of -0.62 and a beta of 1.39. Aspira Women’s Health has a 52 week low of $0.67 and a 52 week high of $5.65. The firm’s 50-day simple moving average is $0.83 and its two-hundred day simple moving average is $1.12.
Institutional Trading of Aspira Women’s Health
An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH – Free Report) by 88.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 12.19% of the company’s stock.
Aspira Women’s Health Company Profile
Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.
Further Reading
- Five stocks we like better than Aspira Women’s Health
- How to Effectively Use the MarketBeat Ratings Screener
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- What Are Dividend Contenders? Investing in Dividend Contenders
- Texas Instruments: The Old-School Tech Titan Still Delivering
- With Risk Tolerance, One Size Does Not Fit All
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with MarketBeat.com's FREE daily email newsletter.
